Repligen Corporation (RGEN) 是一家上市公司 屬於 醫療保健 板塊，經營於 Medical - Instruments & Supplies 產業. 公司總部位於 Waltham, MA, 美国. 現任CEO為 Olivier Loeillot.
RGEN 擁有 IPO日期為 1986-04-29, 1,778 名全職員工, 在 NASDAQ Global Select, 市值為 $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
